These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
333 related articles for article (PubMed ID: 8487046)
1. Randomized comparison of 36-hour intermediate-dose versus 4-hour high-dose methotrexate infusions for remission induction in relapsed childhood acute lymphoblastic leukemia. Wolfrom C; Hartmann R; Fengler R; Brühmüller S; Ingwersen A; Henze G J Clin Oncol; 1993 May; 11(5):827-33. PubMed ID: 8487046 [TBL] [Abstract][Full Text] [Related]
2. Randomized comparison of moderate-dose methotrexate infusions to oral methotrexate in children with intermediate risk acute lymphoblastic leukemia: a Childrens Cancer Group study. Lange BJ; Blatt J; Sather HN; Meadows AT Med Pediatr Oncol; 1996 Jul; 27(1):15-20. PubMed ID: 8614385 [TBL] [Abstract][Full Text] [Related]
3. Comparison of two schedules of intermediate-dose methotrexate and cytarabine consolidation therapy for childhood B-precursor cell acute lymphoblastic leukemia: a Pediatric Oncology Group study. Land VJ; Shuster JJ; Crist WM; Ravindranath Y; Harris MB; Krance RA; Pinkel D; Pullen DJ J Clin Oncol; 1994 Sep; 12(9):1939-45. PubMed ID: 8083715 [TBL] [Abstract][Full Text] [Related]
4. Value of high-dose cytarabine during interval therapy of a Berlin-Frankfurt-Munster-based protocol in increased-risk children with acute lymphoblastic leukemia and lymphoblastic lymphoma: results of the European Organization for Research and Treatment of Cancer 58881 randomized phase III trial. Millot F; Suciu S; Philippe N; Benoit Y; Mazingue F; Uyttebroeck A; Lutz P; Mechinaud F; Robert A; Boutard P; Marguerite G; Ferster A; Plouvier E; Rialland X; Behard C; Plantaz D; Dresse MF; Philippet P; Norton L; Thyss A; Dastugue N; Waterkeyn C; Vilmer E; Otten J; J Clin Oncol; 2001 Apr; 19(7):1935-42. PubMed ID: 11283125 [TBL] [Abstract][Full Text] [Related]
5. Acute neurotoxicity in children with B-precursor acute lymphoid leukemia: an association with intermediate-dose intravenous methotrexate and intrathecal triple therapy--a Pediatric Oncology Group study. Mahoney DH; Shuster JJ; Nitschke R; Lauer SJ; Steuber CP; Winick N; Camitta B J Clin Oncol; 1998 May; 16(5):1712-22. PubMed ID: 9586883 [TBL] [Abstract][Full Text] [Related]
6. A randomized trial of induction therapy (daunorubicin, vincristine, prednisone versus daunorubicin, vincristine, prednisone, cytarabine and 6-thioguanine) in adult acute lymphoblastic leukemia with long-term follow-up: an Eastern Cooperative Oncology Group Study (E3486). Wiernik PH; Cassileth PA; Leong T; Hoagland HC; Bennett JM; Paietta E; Oken MM; Leuk Lymphoma; 2003 Sep; 44(9):1515-21. PubMed ID: 14565653 [TBL] [Abstract][Full Text] [Related]
7. Repetitive low dose oral methotrexate and intravenous mercaptopurine treatment for patients with lower risk B-lineage acute lymphoblastic leukemia. A Pediatric Oncology Group pilot study. Mahoney DH; Camitta BM; Leventhal BG; Shuster JJ; Civin CJ; Ganick DJ; Lauer SJ; Steuber CP; Kamen BA Cancer; 1995 May; 75(10):2623-31. PubMed ID: 7736409 [TBL] [Abstract][Full Text] [Related]
8. High-dose mercaptopurine followed by intermediate-dose cytarabine in relapsed acute leukemia. Lockhart S; Plunkett W; Jeha S; Ramirez I; Zipf T; Cork A; Pinkel D J Clin Oncol; 1994 Mar; 12(3):587-95. PubMed ID: 8120558 [TBL] [Abstract][Full Text] [Related]
9. Extended triple intrathecal chemotherapy trial for prevention of CNS relapse in good-risk and poor-risk patients with B-progenitor acute lymphoblastic leukemia: a Pediatric Oncology Group study. Pullen J; Boyett J; Shuster J; Crist W; Land V; Frankel L; Iyer R; Backstrom L; van Eys J; Harris M J Clin Oncol; 1993 May; 11(5):839-49. PubMed ID: 8487048 [TBL] [Abstract][Full Text] [Related]
11. Extended intrathecal methotrexate may replace cranial irradiation for prevention of CNS relapse in children with intermediate-risk acute lymphoblastic leukemia treated with Berlin-Frankfurt-Münster-based intensive chemotherapy. The Associazione Italiana di Ematologia ed Oncologia Pediatrica. Conter V; Aricò M; Valsecchi MG; Rizzari C; Testi AM; Messina C; Mori PG; Miniero R; Colella R; Basso G J Clin Oncol; 1995 Oct; 13(10):2497-502. PubMed ID: 7595699 [TBL] [Abstract][Full Text] [Related]
12. Intermediate-dose methotrexate versus cranial irradiation in childhood acute lymphoblastic leukemia: a ten-year follow-up. Freeman AI; Boyett JM; Glicksman AS; Brecher ML; Leventhal BG; Sinks LF; Holland JF Med Pediatr Oncol; 1997 Feb; 28(2):98-107. PubMed ID: 8986145 [TBL] [Abstract][Full Text] [Related]
13. A phase II study of combined methotrexate and teniposide infusions prior to reinduction therapy in relapsed childhood acute lymphoblastic leukemia: a Pediatric Oncology Group study. Ochs J; Rodman J; Abromowitch M; Kavanagh R; Harris M; Yalowich J; Rivera GK J Clin Oncol; 1991 Jan; 9(1):139-44. PubMed ID: 1985163 [TBL] [Abstract][Full Text] [Related]
14. Combination therapy with methotrexate, vincristine, polyethylene-glycol conjugated-asparaginase, and prednisone in the treatment of patients with refractory or recurrent acute lymphoblastic leukemia. Aguayo A; Cortes J; Thomas D; Pierce S; Keating M; Kantarjian H Cancer; 1999 Oct; 86(7):1203-9. PubMed ID: 10506705 [TBL] [Abstract][Full Text] [Related]
16. Intermediate-dose intravenous methotrexate and mercaptopurine therapy for non-T, non-B acute lymphocytic leukemia of childhood: a Pediatric Oncology Group study. Camitta B; Leventhal B; Lauer S; Shuster JJ; Adair S; Casper J; Civin C; Graham M; Mahoney D; Munoz L J Clin Oncol; 1989 Oct; 7(10):1539-44. PubMed ID: 2778483 [TBL] [Abstract][Full Text] [Related]
17. Intermediate dose methotrexate is as effective as high dose methotrexate in preventing isolated testicular relapse in childhood acute lymphoblastic leukemia. Dördelmann M; Reiter A; Zimmermann M; Fengler R; Henze G; Riehm H; Schrappe M J Pediatr Hematol Oncol; 1998; 20(5):444-50. PubMed ID: 9787317 [TBL] [Abstract][Full Text] [Related]
18. Toxic epidermal necrolysis following combination of methotrexate and trimethoprim-sulfamethoxazole. Yang CH; Yang LJ; Jaing TH; Chan HL Int J Dermatol; 2000 Aug; 39(8):621-3. PubMed ID: 10971734 [TBL] [Abstract][Full Text] [Related]
19. Intermediate-dose intravenous methotrexate with intravenous mercaptopurine is superior to repetitive low-dose oral methotrexate with intravenous mercaptopurine for children with lower-risk B-lineage acute lymphoblastic leukemia: a Pediatric Oncology Group phase III trial. Mahoney DH; Shuster J; Nitschke R; Lauer SJ; Winick N; Steuber CP; Camitta B J Clin Oncol; 1998 Jan; 16(1):246-54. PubMed ID: 9440749 [TBL] [Abstract][Full Text] [Related]
20. High-dose methotrexate as part of remission maintenance therapy for childhood acute lymphocytic leukemia: a Pediatric Oncology Group pilot study. Frankel LS; Wang YM; Shuster J; Nitschke R; Doering EJ; Pullen J J Clin Oncol; 1983 Dec; 1(12):804-9. PubMed ID: 6583318 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]